

We are IntechOpen, the world's leading publisher of Open Access books Built by scientists, for scientists

6,900

Open access books available

186,000

International authors and editors

200M

Downloads

Our authors are among the

154

Countries delivered to

TOP 1%

most cited scientists

12.2%

Contributors from top 500 universities



WEB OF SCIENCE™

Selection of our books indexed in the Book Citation Index
in Web of Science™ Core Collection (BKCI)

Interested in publishing with us?
Contact book.department@intechopen.com

Numbers displayed above are based on latest data collected.
For more information visit www.intechopen.com



Bone Marrow Microenvironment in the Pathogenesis of AML

Olga Blau

Charité University School of Medicine
Germany

1. Introduction

Acute myeloid leukemia (AML) arises from a series of genetic abnormalities in a stem or progenitor cell that lead to uncontrolled growth. Data from the past few decades have implicated the hematopoietic microenvironment (HM) in the pathogenesis of hematologic malignancies (Ramakrishnan et al., 2009). Hematopoietic stem cells (HSCs) live in a highly specialized complex microenvironment, also known as a niche (Scadden et al., 2007; Konopleva et al., 2009). Two distinct microenvironmental niches defined: “osteoblastic (endosteal)” and “vascular” niches (Perry and Li, 2007). Recent studies suggest that these niches work together. Coordination between the osteoblastic and vascular niches regulates HSC selfrenewal, proliferation, differentiation and mobilization in and out of the bone marrow (BM). HSCs leave the osteoblastic niche, mobilize to the vascular niche, and enter the blood vessel. They subsequently may undergo transendothelial migration from the peripheral circulation and return first to the vascular niche and then to the osteoblastic niche (Lapidot et al., 2005; Cancelas and Williams, 2006). Within the niche, there are critical bidirectional signals that ensure the regulation of normal HSCs (Calvi et al., 2003) and maintenance of the quiescent long-term HSC pool (Fleming et al., 2008). The quiescent fraction of immunophenotypically defined HSCs has been previously demonstrated to correlate with long-term repopulating ability of BM (Passegue et al., 2005) and loss of this fraction is associated with inability to sustain serial transplantation, the most stringent *in vivo* assay of self-renewal (Fleming et al., 2008).

The HM consists of a complex structure of both non-hematopoietic and hematopoietic cells, extracellular matrix as well as soluble and membrane bound factors that cooperate to support normal hematopoiesis. It was known as early as the 1960s, based on experiments on mice, that normal hematopoiesis could not occur without a supportive environment (Russell et al., 1979). *In vitro* studies of the HM over the last several decades have mostly relied on the long-term marrow culture system, first reported by Dexter (1977).

The key component of the HM is mesenchymal stromal cells (MSC). These plastic-adherent cells currently described as mesenchymal stem cells are termed multipotent mesenchymal stromal cells, while the term mesenchymal stem cell should be reserved for a subset of these cells that demonstrate stem cell activity by clearly stated criteria (Horowitz et al., 2005). MSCs are primitive cells originating from the mesodermal germ layer and were classically described to give rise to connective tissues, skeletal muscle cells, and cells of the vascular system. Friedenstein and colleagues (1974) first described MSC as fibroblast-like cells that

could be isolated from BM via inherent adherence to plastic in culture. He defined a population of cells as multipotential stromal precursor cells that were spindle-shaped and clonogenic in culture conditions, defining them as colony-forming unit fibroblasts. MSCs, in the traditional view, should refer to stem cells that are also capable of producing blood cells; however, blood cells are actually derived from a distinct cell population called the hematopoietic stem cells. This allows classified MSC as nonhematopoietic, multipotential stem cells that are capable of differentiating into mesenchymal and non-mesenchymal cell lineages (Chamberlain et al., 2007). These cells were able to differentiate into adipocytes, chondrocytes, osteocytes, and myoblasts, both *in vitro* and *in vivo*. In addition, it has also been demonstrated that MSCs are capable of differentiating into cardiomyocytes, neurons, and astrocytes *in vitro* and *in vivo* (Pittenger et al., 1999; Jori et al., 2005; Beyer Nardi et al., 2006; Tokcaer-Keskin et al., 2009). By generating functionally distinct cell types and structures, MSC play a crucial role in supporting hematopoiesis as key components of the HM (Sacchetti et al., 2007).

Phenotypically MSCs express a number of markers, none of which are specific only to MSCs. It is generally agreed that adult human MSCs do not express the hematopoietic markers CD45, CD34, CD14, or CD11. They also do not express the costimulatory molecules CD80, CD86, or CD40 or the adhesion molecules CD31, CD18, or CD56, but they can express CD105 (SH2), CD73 (SH3/4), CD44, CD90 (Thy-1), CD71, and Stro-1 as well as the adhesion molecules CD106, CD166, intercellular adhesion molecule, and CD29 (Sordi et al., 2005; Chamberlain et al., 2007). Although there are no unique cell surface markers for the identification of MSCs, minimal criteria to define human MSC have been published. According to such criteria, MSC must be plastic-adherent; and have to express CD105, CD90 and CD73; they must lack expression of CD45, CD34 and CD14; and they must show *in vitro* differentiation capabilities into osteoblasts, adipocytes and chondroblasts (Horowitz et al., 2005; Chamberlain et al., 2007). This *in vitro* system has allowed for the dissection of the components of the microenvironment and the study of the complex contact dependent and contact independent interactions that occur between the stromal compartment and hematopoietic stem cells that regulate stem cell fate decisions.

Normal hematopoiesis requires complex bidirectional interactions between the HM and HSCs. The HM can regulate hematopoiesis by interacting directly with HC and/or by secreting regulatory molecules that exert a positive or negative influence on the growth of HC. These interactions influence HSC self-renewal. HM controls the formation of blood cells through the production and secretion of cytokines, chemokines, and intracellular signals initiated by cellular adhesion (Konopleva et al., 2009). Chemokines are a large superfamily of small glycoproteins that are required in a various series of biological processes, including leukocyte trafficking, hematopoiesis, angiogenesis, and organogenesis. MSCs have the ability to migrate into tissues from the circulation, possibly in response to signals that are upregulated under injury conditions. Although the mechanisms by which MSCs are recruited to tissues and cross the endothelial cell layer are not yet fully understood, it is probable that chemokines and their receptors are involved, as they are important factors known to control cell migration (Chamberlain et al., 2007).

CXCL12/stromal cell-derived factor-1 α (SDF-1 α) and its receptor CXCR4 are involved in homing of HSC into BM (Abkowitz et al., 2003; Broxmeyer et al., 2005; Morrison and Spradling, 2008). Perivascular reticular cells secrete much higher levels of CXCL12 than other constitutive sources of CXCL12, such as osteoblasts, fibroblasts, and endothelial cells

(Sugiyama et al. 2006). These reticular cells, defined as CXCL12-abundant reticular cells, may serve as a transit pathway for shuttling HSC between the osteoblastic and vascular niches, where essential but different maintenance signals are provided (Perry and Li, 2007). The molecular interactions between HC and MSC involve ligand-receptor relationship between adhesion molecules on the surface of HC and stromal cells or between such molecules on the cells surface with specific domains within certain extracellular matrix molecules. BM engraftment involves subsequent cell-to-cell interactions through the MSC-produced complex extracellular matrix (ECM) (Zuckerman and Wicha, 1983; Wight et al., 1986). Vascular cell-adhesion molecule-1 (VCAM-1) or fibronectin is critical for adhesion to the MSC (Miyake et al., 1991; Garcia-Gila et al., 2002). One very important type of interaction between the MSC and the HSC is the synthesis and presentation by MSC of hematopoietic growth factors. Interactions of HSC with stromal elements of BM play a role in the egress of mature blood cells from the BM (Chamberlain et al., 2007).

Whether MSC alterations influence hematological disorders and how such alterations contribute to the progression of the disease remains controversial. The molecular mechanisms for maintaining quiescence of normal stem cells may also facilitate leukemia stem cells (LSC) survival. Whereas LSC share certain features of self-renewal and differentiation with HSC, LSC differ in their deregulated proliferation and ability to invade and spread. LSC exhibit the capacity for long-term self-renewal (Holyoake et al., 2002; Warner et al., 2004; Liesveld et al., 2004) within the BM microenvironment, which is required for maintenance of the malignant clone (Braun and Shannon, 2008). LSCs are able to generate leukemic blasts, and the leukemic clone is organized as a hierarchy (Zhang et al., 2003). LSCs may steal the homeostatic mechanisms, take refuge within the HM during chemotherapy, and consequently contribute to eventual disease relapse (Warner et al., 2004; Lane et al., 2009). Consecutively, LSC are believed to arise through transforming events targeting HSC, which allow growth-independent survival and proliferation. MSC are capable of promoting the growth, survival and drug resistance of leukemic cells by providing the necessary cytokines and cell contact-mediated signals to LSC (Dazzi et al., 2006; Ramasamy et al., 2007). There is increasing evidence that microenvironment alterations may be important and pathogenic in leukemia leading to enhanced stem cell mobilization and the creation of alternate niches (Lataillade et al., 2008). Recent data indicate that, in parallel with leukemogenic events in the hematopoietic system, the niche is converted into an environment with dominant signals favoring cell proliferation and growth. In some cases, a combination of these events may be required (Li and Neaves, 2006). Therefore, LSC may receive the support of a BM niche for their survival and may in turn influence deregulation of the BM niche by their dominant proliferation-promoting signals.

AML may arise in an abnormal HM, resulting in the generation of multiple populations with varying initiation events. Ninomiya et al. (2007) modeled the homing, proliferation, and survival sites of human leukemia cells and of cord blood CD34⁺ cells. The transplanted leukemia cells initially localized on the surface of osteoblasts in the epiphysial region and then expanded to the inner vascular and diaphysial regions. 8 weeks after transplantation, the number of leukemia cells transiently increased by as much as 50%, predominantly in the epiphysial region. After administration of high-dose cytarabine, residual leukemia cells clustered and adhered to the blood vessels as well as to the endosteum, suggesting that leukemia cells receive anti-apoptotic signals not only from osteoblasts but also from vascular endothelium (Ninomiya et al., 2007).

Several studies have proposed that important quantitative and functional alterations occur in MSCs of patients with different hematological disorders (Borojevic et al., 2004; Flores-Figueroa et al., 2008). In some disorders, such as multiple myeloma, MSC show alterations in the expression of some cell adhesion molecules and cytokines, and reduced immunosuppressive efficiency (Wallace et al., 2001; Arnulf et al., 2007; Corre et al., 2007). Neoplastic plasma cells communicate with the environment through cell/cell contact as well cytokines to induce functional changes that support the malignant population (Mitsiades et al., 2006; Podar et al., 2007). In myeloproliferative disorders, has been shown, that megakaryocytes and macrophages play a principle role in the pathogenesis of the fibrotic reaction by secreting PDGF, FGF and TGF α cytokines (Chagraoui et al., 2006). In chronic myeloid leukemia (CML), Bhatia (1995) showed that MSC did not provide optimal support for normal hematopoietic cells. In contrast, growth of CML cells on CML-derived stroma was significantly better, suggesting that the microenvironment in CML was more supportive for the malignant clone. Using fluorescent activated cell sorting (FACS) and fluorescent in situ hybridization (FISH), it was determined that stromal macrophages were all bcr-abl positive and were directly responsible for the selective advantage of clonal bcr-abl cells to proliferate through a contact-dependent mechanism (Bhatia et al. 1995). Interestingly, other researches estimated that CML-derived MSC do not express the bcr-abl gene (Zhao et al., 2006; Jootar et al., 2006). In myelodysplastic syndrome (MDS) MSC show alterations in the levels of TNF α (Deeg et al., 2000). Furthermore, the MDS-derived monocytes respond abnormally to stromal signals, MDS monocytes fail to upregulate matrix metalloproteinase-9 (MMP-9) expression when exposed to stromal signals (Iwata et al., 2007). MMP-9 has been implicated in the cleavage of SDF1 from the microenvironment and may facilitate the egress of HCs from the BM to the peripheral blood (Heissig et al., 2002). In the solid tumors, tumor-derived MSC shown acquire aberrant methylation patterns due either to direct contact with or via factors secreted by the malignant cells (Hanson et al., 2006; Fiegl et al., 2006).

Dysfunction of a BM niche may contribute to leukemogenesis by supplying abundant growth factors that promote proliferation and/or inhibit apoptosis (Jones and Wagers, 2008). MSCs seem to have a relevant role in AML as they prevent spontaneous and induced apoptosis and may attenuate chemotherapy-induced cell death. This possibility has been confirmed by the finding that co-cultivation of a leukemic cell line with the murine stroma cell line MS-5 can block apoptosis (Konopleva et al., 2002).

The significance role of the HM in initiation of leukemia has been suggested by studies with mice deficient in phosphatase and tensin homolog (PTEN) (Yilmaz et al., 2006). PTEN deficiency in both HSC and the HM resulted in myeloproliferation that progressed to overt leukemia/lymphoma. However, inducible PTEN deletion in HSC in the presence of a wild type HM promoted HSC depletion without evidence of myeloproliferation or leukemic development. These results suggest that PTEN deficiency in HSC alone is not sufficient for malignant transformation. Rupec et al. (2005) reported that activation of NF- κ B in myelopoietic cells and the absence of its inhibitor I κ B α are not sufficient for induction of hypergranulopoiesis, but these changes in the non-hematopoietic compartment, such as fetal liver, resulted in increased numbers of dysplastic hematopoietic cells with progression into secondary AML. These results indicate that non-hematopoietic cells with inactive I κ B α can initiate premalignant hematopoietic disorder, conceivably via activation of the Notch pathway. Additional studies indicate the role of Notch signaling in the interactions of HSC

and the HM (Matsuoka et al., 2008) demonstrated that the tumor suppressor Fbxw7, which negatively regulates cyclin E, Notch, and c-Myc protein levels, plays a role in maintaining HSC quiescence and repressing potential oncogenic activity of HSC. Notably, Notch ligand Jagged is expressed by the HSC niche, and Jagged/Notch activation results in increased HSC number and niche expansion (Calvi et al., 2003).

Evidence from research conducted over the last few decades has clearly implicated abnormalities of the marrow microenvironment in the pathophysiology of hematologic malignancies. Marcondes et al. (2008) demonstrated that MSC derived from patients with MDS, in contrast to that from more advanced stages of MDS expressed 14- to 17-fold higher levels of IL-32 mRNA than healthy controls, and this constitutive IL-32 expression promoted apoptosis in MDS cells, reproducing the inefficient hematopoiesis and extensive apoptosis in MDS marrow. These findings indicate that stroma-produced IL-32 could contribute to the pathophysiology of MDS, and serve as a therapeutic target. Furthermore, this modified microenvironment phenotype was reproduced when the MSC were exposed to TNF α , known to be produced at high levels by MDS cells.

There are significant data to support mechanism, in which the malignant hematopoietic clone induces reversible functional changes in the HM that result in improved growth conditions for the malignant cells. Gene expression changes occurred in the stroma cell lines, HS5 and HS27a, derived from normal marrow in response to TNF α exposure (Stirewalt et al., 2008), known to be up-regulated in the bone marrow of patients with MDS. Previous experiments showed that interactions between MSC and HSC were required for TNF α to trigger apoptosis in hematopoietic cells (Goda et al., 2006).

Recent discoveries utilizing mouse models have provided the first experimental evidence for genetic changes in the HM contributing to or required for leukemogenesis. Raaijmakers et al. (2010) using transgenic mice showed that genetic alteration of HM can induce MDS with ineffective hematopoiesis and dysmorphic HCs, and with occasional transformation to AML. The authors used *Dicer1* deletion as a means of altering several gene products in subsets of mesenchymal osteolineage cells. *Dicer1* is an RNase III endonuclease essential for microRNA biogenesis (Bartel, 2004) and RNA processing (Krol et al., 2007), that regulates haematopoietic cell fate (Lu et al., 2008). Global repression of microRNA maturation by *Dicer1* deletion promotes cellular transformation and tumorigenesis (Kumar et al., 2007). Raaijmakers et al. (2010) show that deletion of *Dicer1* in HM cells of mouse may be sufficient to initiate a complex change of homeostasis with similarities to myelodysplasia. The authors demonstrated that the ability of HM abnormality to result in the emergence of a clonal neoplasm in a cell type of clearly distinct lineage with distinct secondary genetic changes (Raaijmakers et al., 2010).

Previously, Walkley et al (2007a, 2007b) demonstrated that conditional deletion of the Retinoblastoma gene (RB) in the BM microenvironment can contribute to the development of pre-leukemic myeloproliferative disease in mice. They showed that this was a result of interactions between myeloid cells and the microenvironment. The defect had to be present in both hematopoietic cells and the microenvironment to initiate disease. Widespread inactivation of RB, a central regulator of the cell cycle and a tumor suppressor, resulted in extramedullary hematopoiesis and myeloproliferative disease in the murine hematopoietic system. However, myeloid-specific loss of RB did not induce myeloproliferative disease or HSC abnormalities. Therefore, the myeloproliferative-like disorder in the RB mutants is the result of perturbed interactions between hematopoietic cells and the BM microenvironment

(Walkley et al., 2007a). The final model, reported by the same group, may be the most compelling. In this report, deletion of the Retinoic Acid Receptor γ (RAR γ) in mice resulted in a chronic myeloproliferative disorder. Transplant studies revealed that RAR γ -hematopoietic cells functioned normally when transplanted into normal mice. However, transplantation of normal hematopoietic cells into the RAR γ -microenvironment resulted in a myeloproliferative disorder in the transplanted cells. TNF α was implicated in the pathogenesis of this MPD as the disorder was partially abrogated when TNF α null stem cells were transplanted into the RAR γ -microenvironment (Walkley et al., 2007b). These studies showed that a defect in HM could be sufficient to generate a myeloproliferative disorder.

Until recently, there has been little evidence to support the role of primary stromal abnormalities in the pathogenesis of hematologic neoplasms. Some independent studies have documented the existence of genomic alterations in the stroma of leukemia patients (Flores-Figueroa et al., 2005; Blau et al., 2007; Lopez-Villar et al., 2009; Klaus et al., 2010). Different groups have shown the extensive variability of the aberrations, such as hypodiploidy, balanced and unbalanced translocations, whole chromosome gains, and deletions. All cytogenetic markers in MSCs never repeated aberrations identified in HCs. Since there were no associations between chromosomal aberrations in HCs and MSCs, we can state that MSCs were devoid of residue HCs. These findings suggest enhanced genetic instability of MSC in leukemia, and indicate the potential involvement of MSC in the pathophysiology of these conditions (Blau et al., 2007). Recently, Lopez-Villar et al. (2009) reported the presence of cytogenetic aberrations on MSC from MDS patients by array-based comparative genomic hybridization and fluorescence in situ hybridization, some of them specially linked to a particular MDS subtype, the 5q-syndrome.

These data indicate that there are significant functional abnormalities, genetic aberrations, and epigenetic changes in MSC in leukemia patients. Also of interest are the recent reports of abnormalities in the stroma that lead to malignancies of the hematopoietic compartment. Although historically, hematologic malignancies are thought to arise from a stem or progenitor cell abnormality, there may be groups of patients that have a primary stromal defect leading to the hematologic malignancy. Moreover, although a series of genetic and epigenetic events in a single cell may be necessary for oncogenesis, they may not be sufficient, and a permissive microenvironment has been suggested to be required for frank malignancy to emerge (Hanahan and Weinberg, 2007).

It is known that even years after allogeneic stem cell transplantation (alloSCT), and despite successful engraftment of donor-derived hematopoiesis, MSC are in general of host origin (Rieger et al., 2005). Some patients after alloSCT do not recover their stem cells despite receiving high levels of CD34 $^{+}$ progenitor cells. The presumed basis for this is that the preparation regimen has in some way affected the niche, so it no longer has the same nurturing capability. It was shown that transplanted HSCs migrate to the endosteal surfaces of bone within hours of intravenous injection (Nilsson et al., 1997). Endochondral ossification has been shown to be an essential prerequisite for the development of normal haematopoiesis in the BM (Zhou et al., 1995), indicating a possible fundamental interrelationship of ossification to the mature haematopoietic process in mammals. Recent reports have identified that a key cellular component of the HSC niche is cells of the osteoblast lineage, the cell type responsible for the formation of bone (Calvi et al., 2003; Zhang et al., 2003). Additionally, these studies raise the issue that under transplant

conditions, there may be agents that rather than drive hematopoiesis, might affect the osteoblast component.

Understanding the niche has ramifications beyond simple biological interest. Niche biology and function has relevance not only in bone marrow transplantation, but in developing agents that may impact on the ability to generate a larger number of stem cells or increase the efficiency of stem cells to engraft in the transplant setting. By elucidating the role of the BM microenvironment in the pathogenesis of hematologic tumors, recent studies have provided the framework for identifying and validating novel therapies that target both leukemic cells and cells in their surrounding microenvironment (Konopleva et al., 2009). Thus in general, treatment strategies have been focused on the eradication of the stem or progenitor cell from which the malignancy arose. However, recent evidence suggests that focusing therapeutic strategies on the microenvironmental abnormalities can be extremely effective. The Imid family of agents has changed the treatment paradigm in diseases such as myeloma and MDS and highlighted the importance of targeting the microenvironment (Sokol et al., 2007; Melchert and List, 2007).

If primary stromal defects are identified in humans and implicated in the initiation of malignancy, this clearly will have great impact on the treatment strategies offered to patients. By explanation the role of the MSC in the pathogenesis of AML, recent studies have provided novel therapies that target both leukemic cells and cells of microenvironment. Studies of MSC can also aid in potentially modifying the relative abundance of normal versus malignant cells in the context of the post chemotherapy setting in AML. The underlying molecular mechanisms implicated in stem cell activation and homing to the niche will provide important insight into the precise mechanisms involved in interactions between leukemic and normal cells that contribute to drug resistance. This understanding will provide a framework for the rational combination of agents in clinical trials to overcome drug resistance and improve patient outcomes. Detection of alterations in MSCs suggests that unstable MSCs may facilitate the expansion of malignant cells. In view of these data, alterations in MSCs may be a particular mechanism of leukemogenesis. Especially, further understanding of the contribution of the BM niche to the process of leukemogenesis may provide new targets aimed at destroying LSC without adversely affecting normal stem cell self-renewal.

2. References

- Abkowitz JL, Robinson AE, Kale S, Long MW, Chen J. Mobilization of hematopoietic stem cells during homeostasis and after cytokine exposure. *Blood* 2003;102:1249-1253.
- Arnulf B, Lecourt S, Soulier J et al. Phenotypic and functional characterization of bone marrow mesenchymal stem cells derived from patients with multiple myeloma. *Leukemia* 2007;21:158-63.
- Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. *Cell* 2004;116:281-297.
- Beyer Nardi N, da Silva Meirelles L. Mesenchymal stem cells: Isolation, in vitro expansion and characterization. *Handb Exp Pharmacol* 2006:249-282.
- Bhatia R, McGlave PB, Dewald GW et al. Abnormal function of the bone marrow microenvironment in chronic myelogenous leukemia: Role of malignant stromal macrophages. *Blood* 1995;85:3636-3645.

- Blau O, Hofmann WK, Baldus CD et al. Chromosomal aberrations in bone marrow mesenchymal stroma cells from patients with myelodysplastic syndrome and acute myeloblastic leukemia. *Exp Hematol* 2007;35(2):221-229.
- Borojevic R, Roela R, Rodarte R et al. Bone marrow stroma in childhood myelodysplastic syndrome: composition, ability to sustain hematopoiesis in vitro, and altered gene expression. *Leuk Res* 2004;28(8):831-844.
- Braun BS, Shannon K. Targeting Ras in myeloid leukemias. *Clin Cancer Res* 2008;14:2249-2252.
- Broxmeyer HE., Orschell CM, Clapp DW et al. Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. *J Exp Med* 2005;201:1307-1318.
- Calvi LM, Adams GB, Weibrecht KW et al. Osteoblastic cells regulate the haematopoietic stem cell niche. *Nature* 2003;425:841-846.
- Cancelas JA, Williams DA. Stem cell mobilization by beta2-agonists. *Nat Med* 2006;12:278-279.
- Chagraoui H, Wendling F, Vainchenker W. Pathogenesis of myelofibrosis with myeloid metaplasia: Insight from mouse models (Review). *Best Pract Res Clin Haematol* 2006;19:399-412.
- Chamberlain G, Fox J, Ashton B, Middleton J. Concise Review: Mesenchymal Stem Cells: Their Phenotype, Differentiation Capacity, Immunological Features, and Potential for Homing. *Stem Cells* 2007;25:2739-2749.
- Corre J, Mahtouk K, Attal M et al. Bone marrow mesenchymal stem cells are abnormal in multiple myeloma. *Leukemia* 2007;21:1079-1088.
- Dazzi F, Ramasamy R, Glennie S, Jones SP, Roberts I. The role of mesenchymal stem cells in haemopoiesis. *Blood Rev* 2006;20:161-171.
- Deeg HJ, Beckham C, Loken MR et al. Negative regulators of hemopoiesis and stroma function in patients with myelodysplastic syndrome. *Leuk Lymphoma* 2000;37:405-414.
- Dexter TM, Allen TD, Lajtha LG. Conditions controlling the proliferation of haemopoietic stem cells in vitro. *J Cell Physiol* 1977;91:335-344.
- Fiegl H, Millinger S, Goebel G et al. Breast cancer DNA methylation profiles in cancer cells and tumor stroma: association with HER-2/neu status in primary breast cancer. *Cancer Res* 2006;66:29-33.
- Fleming HE, Janzen V, Lo Celso C et al. Wnt signaling in the niche enforces hematopoietic stem cell quiescence and is necessary to preserve self-renewal in vivo. *Cell Stem Cell* 2008;2:274-283.
- Flores-Figueroa E, Arana-Trejo RM, Gutiérrez-Espíndola G, Pérez-Cabrera A, Mayani H. Mesenchymal stem cells in myelodysplastic syndromes: phenotypic and cytogenetic characterization. *Leuk Res* 2005;29(2):215-224.
- Flores-Figueroa E, Montesinos JJ, Flores-Guzman P et al. Functional analysis of myelodysplastic syndromes-derived mesenchymal stem cells. *Leuk Res* 2008;32:1407-1416.
- Friedenstein AJ, Chailakhyan RK, Latsinik NV et al. Stromal cells responsible for transferring the microenvironment of the hemopoietic tissues. Cloning in vitro and retransplantation in vivo. *Transplantation* 1974;17:33-40.

- Garcia-Gila M, Lopez-Martin EM, Garcia-Pardo A. Adhesion to fibronectin via alpha4 integrin (CD49d) protects B cells from apoptosis induced by serum deprivation but not via IgM or Fas/ Apo-1 receptors. *Clin Exp Immunol* 2002;127:455–462.
- Goda C, Kanaji T, Kanaji S et al. Involvement of IL-32 in activation-induced cell death in T cells. *Int Immunol* 2006;18:233–240.
- Hanahan D, Weinberg RA. The hallmarks of cancer. *Cell* 2000;100:57–70.
- Hanson JA, Gillespie JW, Grover A et al. Gene promoter methylation in prostate tumor-associated stromal cells. *J Natl Cancer Inst* 2006;98:255–261.
- Heissig B, Hattori K, Dias S et al. Recruitment of stem and progenitor cells from the bone marrow niche requires MMP-9 mediated release of kit-ligand. *Cell* 2002;109:625–637.
- Holyoake TL, Jiang X, Drummond MW, Eaves AC, Eaves CJ. Elucidating critical mechanisms of deregulated stem cell turnover in the chronic phase of chronic myeloid leukemia. *Leukemia* 2002;16:549–558.
- Horwitz EM, Le Blanc K, Dominici M et al. Clarification of the nomenclature for MSC: The International Society for Cellular Therapy position statement. *Cytotherapy* 2005;5:393–395.
- Iwata M, Pillai M, Ramakrishnan A et al. Reduced expression of inducible gelatinase B/matrix metalloproteinase-9 in monocytes from patients with myelodysplastic syndrome: correlation of inducible levels with the percentage of cytogenetically marked cells and with marrow cellularity. *Blood* 2007;109:85–92.
- Jones DL, Wagers AJ. No place like home: anatomy and function of the stem cell niche. *Nat Rev Mol Cell Biol* 2008;9:11–21.
- Jootar S, Pornprasertsud N, Petvises S et al. Bone marrowderived mesenchymal stem cells from chronic myeloid leukemia t(9;22) patients are devoid of Philadelphia chromosome and support cord blood stem cell expansion. *Leuk Res* 2006;30:1493–1498.
- Jori FP, Napolitano MA, Melone MA et al. Molecular pathways involved in neural in vitro differentiation of marrow stromal stem cells. *J Cell Biochem* 2005;94:645–655.
- Klaus M, Stavroulaki E, Kastrinaki MC et al. Reserves, Functional, Immunoregulatory, and Cytogenetic Properties of Bone Marrow Mesenchymal Stem Cells in Patients with Myelodysplastic Syndromes. *Stem Cells Dev* 2010;19(7):1043–1055.
- Konopleva M, Tabe Y, Zeng Z, Andreeff M. Therapeutic targeting of microenvironmental interactions in leukemia: mechanisms and approaches. *Drug Resist Updat* 2009;12(4):103–113.
- Konopleva M, Konoplev S, Hu W et al. Stromal cells prevent apoptosis of AML cells by up-regulation of antiapoptotic proteins. *Leukemia* 2002;16:1713–1724.
- Krol J, Fiszer A, Mykowska A et al. Ribonuclease dicer cleaves triplet repeat hairpins into shorter repeats that silence specific targets. *Mol Cell* 2007;25:575–586.
- Kumar MS, Lu J, Mercer KL, Golub TR, Jacks T. Impaired microRNA processing enhances cellular transformation and tumorigenesis. *Nature Genet.* 2007;39:673–677.
- Lane SW, Scadden DT, Gilliland DG. The leukemic stem cell niche: current concepts and therapeutic opportunities. *Blood* 2009 114:1150–1157.
- Lapidot T, Dar A, Kollet O. How do stem cells find their way home? *Blood* 2005;106:1901–1910.


- Lataillade JJ, Pierre-Louis O, Hasselbalch HC et al. Does primary myelofibrosis involve a defective stem cell niche? From concept to evidence. *Blood* 2008;112:3026-3035.
- Li L, Neaves WB. Normal stem cells and cancer stem cells: the niche matters. *Cancer Res* 2006;66:4553-4557.
- Liesveld JL, Jordan CT, Phillips II GL. The hematopoietic stem cell in myelodysplasia. *Stem Cells* 2004;22:590-599.
- Lopez-Villar O, Garcia JL, Sancez-Guijo FM et al. Both expanded and uncultured mesenchymal stem cells from MDS patients are genomically abnormal, showing a specific genetic profile for the 5q- syndrome. *Leukemia* 2009;23:664-672.
- Lu J, Guo S, Ebert BL et al. MicroRNA-mediated control of cell fate in megakaryocyte-erythrocyte progenitors. *Dev Cell* 2008;14:843-853.
- Marcondes AM, Mhyre AJ, Stirewalt DL et al. Dysregulation of IL-32 in myelodysplastic syndrome and chronic myelomonocytic leukemia modulates apoptosis and impairs NK function. *Proc Natl Acad Sci USA* 2008;105:2865-2870.
- Matsuoka S, Oike Y, Onoyama I et al. Fbxw7 acts as a critical fail-safe against premature loss of hematopoietic stem cells and development of T-ALL. *Genes Dev* 2008;22:986-991.
- Melchert M, List A. The thalidomide saga (Review). *Int J Biochem Cell Biol* 2007;39:1489-99.
- Mitsiades CS, Mitsiades NS, Munshi NC et al. The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: interplay of growth factors, their receptors and stromal interactions (Review). *Eur J Cancer* 2006;42:1564-73.
- Miyake K, Medina K, Ishihara K et al. A VCAM-like adhesion molecule on murine bone marrow stromal cells mediates binding of lymphocyte precursors in culture. *J Cell Biol* 1991;114:557-565.
- Morrison SJ, Spradling AC. Stem cells and niches: mechanisms that promote stem cell maintenance throughout life. *Cell* 2008;132:598-611.
- Nilsson SK, Johnston HM, Coverdale JA. Spatial localization of transplanted hemopoietic stem cells: inferences for the localization of stem cell niches. *Blood* 1997;2293-2299.
- Ninomiya M, Abe A, Katsumi A et al. Homing, proliferation and survival sites of human leukemia cells in vivo in immunodeficient mice. *Leukemia* 2007;21:136-142.
- Passequer E, Wagers AJ, Giuriato S, Anderson WC, Weissman IL. Global analysis of proliferation and cell cycle gene expression in the regulation of hematopoietic stem and progenitor cell fates. *J Exp Med* 2005;202:1599-1611.
- Perry JM, Li L. Disrupting the stem cell niche: good seeds in bad soil. *Cell* 2007;129:1045-1047.
- Pittenger MF, Mackay AM, Beck SC et al. Multilineage potential of adult human mesenchymal stem cells. *Science* 1999;284:143-147.
- Podar K, Richardson PG, Hideshima T et al. The malignant clone and the bone marrow environment (Review). *Best Pract Res Clin Haematol* 2007;20:597-612.
- Raaijmakers MH, Mukherjee S, Guo S et al. Bone progenitor dysfunction induces myelodysplasia and secondary leukemia. *Nature* 2010;464:852-857.
- Ramakrishnan A, Deeg HJ. A Novel Role for the Marrow Microenvironment in Initiating and Sustaining Hematopoietic Disease. *Expert Opin Biol Ther* 2009;9(1):21-28.
- Ramasamy R, Lam EW, Soeiro I et al. Mesenchymal stem cells inhibit proliferation and apoptosis of tumor cells: impact on in vivo tumor growth. *Leukemia* 2007;21:304-310.

- Rieger K, Marinets O, Fietz T, Körper S, Sommer D, Mücke C, Reufi B, Blau WI, Thiel E, Knauf WU. Mesenchymal stem cells remain of host origin even a long time after allogeneic peripheral blood stem cell or bone marrow transplantation. *Exp Hematol* 2005;33:605-11.
- Rupec RA, Jundt F, Rebholz B et al. Stroma-mediated dysregulation of myelopoiesis in mice lacking I kappa B alpha. *Immunity* 2005;22:479-491.
- Russell ES. Hereditary anemias of the mouse: a review for geneticists (Review). *Adv Genetics* 1979;20:357-459.
- Sacchetti B, Funari A, Michienzi S et al. Self-renewing osteoprogenitors in bone marrow sinusoids can organize a hematopoietic microenvironment. *Cell* 2007;131:324-336.
- Scadden DT. The stem cell niche in health and leukemic disease. *Best Pract Res Clin Haematol* 2007;20(1):19-27.
- Sokol L, List AF. Immunomodulatory therapy for myelodysplastic syndromes. *Int J Hematol* 2007;86:301-305.
- Sordi V, Malosio ML, Marchesi F et al. Bone marrow mesenchymal stem cells express a restricted set of functionally active chemokine receptors capable of promoting migration to pancreatic islets. *Blood* 2005;106:419 - 427.
- Stirewalt DL, Mhyre AJ, Marcondes M et al. Tumour necrosis factor-induced gene expression in human marrow stroma: clues to the pathophysiology of MDS? *Br J Haematol* 2008;140:444-453.
- Sugiyama T, Kohara H, Noda M, Nagasawa T. Maintenance of the hematopoietic stem cell pool by CXCL12-CXCR4 chemokine signaling in bone marrow stromal cell niches. *Immunity* 2006;25:977-988.
- Tokcaer-Keskin Z, Akar AR, Ayaloglu-Butun F et al. Timing of induction of cardiomyocyte differentiation for in vitro cultured mesenchymal stem cells: A perspective for emergencies. *Can J Physiol Pharmacol* 2009;87:143-150.
- Walkley CR, Shea JM, Sims NA et al. Rb regulates interactions between hematopoietic stem cells and their bone marrow microenvironment. *Cell* 2007a;129:1081-1095.
- Walkley CR, Olsen GH, Dworkin S et al. A microenvironment-induced myeloproliferative syndrome caused by retinoic acid receptor gamma deficiency. *Cell* 2007b;129:1097-1110.
- Wallace SR, Oken MM, Lunetta KL, Panoskaltsis-Mortari A, Masellis AM. Abnormalities of bone marrow mesenchymal cells in multiple myeloma patients. *Cancer* 2001;91:1219-30.
- Warner JK, Wang JC, Hope KJ, Jin L, Dick JE. Concepts of human leukemic development. *Oncogene* 2004;23:7164-7177.
- Wight TN, Kinsella MG, Keating A, Singer JW. Proteoglycans in human long-term bone marrow cultures: biochemical and ultrastructural analyses. *Blood* 1986;67:1333-1343.
- Yilmaz OH, Valdez R, Theisen BK et al. Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. *Nature* 2006;44: 475-482.
- Zhang J, Niu C, Ye L et al. Identification of the haematopoietic stem cell niche and control of the niche size. *Nature* 2003;425:836-841.
- Zhao Z, Tang X, You Y et al. Assessment of bone marrow mesenchymal stem cell biological characteristics and support hematopoiesis function in patients with chronic myeloid leukemia. *Leuk Res* 2006;30:993-1003.

- Zhou H, Choong PFM, Henderson S et al. Marrow development and its relationship to bone formation *in vivo*: a histological study using an implantable titanium device in rabbits. *Bone* 1995; 17:407–415.
- Zuckerman KS, Wicha MS. Extracellular matrix production by the adherent cells of long-term murine bone marrow cultures. *Blood* 1983;61:540–547.

IntechOpen

IntechOpen



Myeloid Leukemia - Basic Mechanisms of Leukemogenesis

Edited by Dr Steffen Koschmieder

ISBN 978-953-307-789-5

Hard cover, 484 pages

Publisher InTech

Published online 14, December, 2011

Published in print edition December, 2011

The current book comprises a series of chapters from experts in the field of myeloid cell biology and myeloid leukemia pathogenesis. It is meant to provide reviews about current knowledge in the area of basic science of acute (AML) and chronic myeloid leukemia (CML) as well as original publications covering specific aspects of these important diseases. Covering the specifics of leukemia biology and pathogenesis by authors from different parts of the World, including America, Europe, Africa, and Asia, this book provides a colorful view on research activities in this field around the globe.

How to reference

In order to correctly reference this scholarly work, feel free to copy and paste the following:

Olga Blau (2011). Bone Marrow Microenvironment in the Pathogenesis of AML, Myeloid Leukemia - Basic Mechanisms of Leukemogenesis, Dr Steffen Koschmieder (Ed.), ISBN: 978-953-307-789-5, InTech, Available from: <http://www.intechopen.com/books/myeloid-leukemia-basic-mechanisms-of-leukemogenesis/bone-marrow-microenvironment-in-the-pathogenesis-of-aml>

INTECH
open science | open minds

InTech Europe

University Campus STeP Ri
Slavka Krautzeka 83/A
51000 Rijeka, Croatia
Phone: +385 (51) 770 447
Fax: +385 (51) 686 166
www.intechopen.com

InTech China

Unit 405, Office Block, Hotel Equatorial Shanghai
No.65, Yan An Road (West), Shanghai, 200040, China
中国上海市延安西路65号上海国际贵都大饭店办公楼405单元
Phone: +86-21-62489820
Fax: +86-21-62489821

© 2011 The Author(s). Licensee IntechOpen. This is an open access article distributed under the terms of the [Creative Commons Attribution 3.0 License](https://creativecommons.org/licenses/by/3.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

IntechOpen

IntechOpen